Skip over navigation
The Hospital
Research
Support Us
Ottawa Hospital Research Institute
Home
Français
Directions & Maps
Contact Us
About Us
Vision and Strategic Directions
Board Chair and CEO Message
Leadership Team
Annual Reports
Facilities
Research Data Management
Equity, Diversity and Inclusion
Wellness
Our Research
Priorities, Programs and Diseases
Researcher Profiles
National Research Networks
Scientific Publications
Research Awards
Technology Transfer
Industry Sponsored Research
Responsible Innovation
For Students & Fellows
News & Events
Newsroom
Seminars & Events
Career Opportunities
For Patients
News & Events
Home
>
News & Events
>
Newsroom
Bookmark or Share
Display Options
Display Options
+
Increase
/
-
Decrease
font size
High contrast version
Printer-friendly version
Newsroom
Seminars & Events
Newsroom
“Revolutionary” hepatitis C therapy at The Ottawa Hospital cures more patients
April 28, 2015
Not long ago, BillyBob McPherson believed he had come to the end of his journey. That assessment would have been fair, were it not for recent advances in the treatment of hepatitis C.
Today, McPherson, a former carnival worker on a disability pension, is disease free, thanks to new drugs developed to cure this devastating infectious disease that affects the liver.
A clinical trial at The Ottawa Hospital led by Dr.
Curtis Cooper
was key to curing McPherson and opening the door to safer and more effective treatment for thousands of others. This particular trial tested a combination of four new anti-viral medications, called the Holkira Pak. The hospital has been involved in developing several other antiviral regimens for hepatitis C as well.
Dr. Cooper, an infectious disease specialist at the hospital and the University of Ottawa, and Director of the Regional Viral Hepatitis Program, said the impact of these new drugs on patients is nothing short of “revolutionary.”
Until recently, hepatitis C treatment was primarily based on a protein called interferon, but side effects were so severe that only a minority of patients could tolerate it.
“Now we have something to offer almost everybody living with hepatitis C that is safe, well-tolerated, of short duration, and highly curative,” explained Dr. Cooper. The rate of cure has jumped from below 50 percent to over 90 percent. While the new treatments are expensive, Dr. Cooper said he believes they will ultimately save the health-care system money by preventing hepatitis C complications such as liver failure and liver cancer.
“Over half of the people with hepatitis C do not know they have it,” he said. “Over the next 10 to 20 years, many of these people will begin to develop liver complications. We are looking at a tidal wave of sick patients.”
About 300,000 Canadians are living with hepatitis C, and many have high levels of poverty, substance abuse and mental health issues. In addition to researching many aspects of this disease, Dr. Cooper and his team are working with psychologists, community partners and telemedicine programs to better engage marginalized populations and develop individualized, patient-focused management plans.
Ottawa Hospital Research Institute
The
Ottawa Hospital Research Institute
is the research arm of
The Ottawa Hospital
and is an affiliated institute of the
University of Ottawa
, closely associated with its faculties of Medicine and Health Sciences. The Ottawa Hospital Research Institute includes more than 1,700 scientists, clinical investigators, graduate students, postdoctoral fellows and staff conducting research to improve the understanding, prevention, diagnosis and treatment of human disease. Support our research. Give to the
Tender Loving Research
campaign.
For further information, please contact
Jennifer Ganton
Director, Communications and Public Relations
Ottawa Hospital Research Institute
Office: 613-737-8899 x73325
Cell: 613-614-5253
jganton@ohri.ca